Dr. Gregory A. Prince was born and reared in Los Angeles, California. He attended Dixie College from 1965-67, graduating as valedictorian. He attended the UCLA School of Dentistry from 1969-73, again graduating as valedictorian. He received a Ph.D. in Pathology from UCLA in 1975, studying respiratory syncytial virus (RSV), the primary cause of infant pneumonia worldwide. Over a period of fifteen years at the National Institutes of Health and Johns Hopkins University, he and his co-workers developed the thesis that RSV disease could be prevented by administering antiviral antibodies to high-risk infants. He co-founded Virion Systems, Inc. to commercialize this thesis, and serves as its President and CEO. In 1989, Virion Systems and MedImmune, Inc. formed a joint venture to conduct clinical trials that ultimately resulted in the licensure by the Food and Drug Administration of RespiGam™ (1996), and Synagis™ (1998) for the prevention of RSV pneumonia in high-risk infants. Synagis™ is the first monoclonal antibody ever licensed for use against any infectious agent. He has published over 150 scientific papers. In addition to a career in science, he has developed an avocation as a historian. His first book, Power From on High: The Development of Mormon Priesthood, was published in 1995; his second, David O. McKay and the Rise of Modern Mormonism, was the recipient of four awards and is in its sixth printing. He and his wife, JaLynn Rasmussen Prince, are the parents of three children. He serves on national advisory boards of six colleges and universities: Johns Hopkins University, Montgomery College, Wesley Theological Seminary, University of Utah, Dixie State College and Utah Valley University.